Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Eligibility Criteria

• 1. Subjects must have histologically or cytologically confirmed metastatic castrate-resistant prostate cancer that has previously been treated with an androgen receptor pathway inhibitor. Prior docetaxel exposure is recommended but not mandatory. Tissue is not mandatory, but a pathologic report is required at time of enrollment.
• 2. Participants must have a PSMA-positive 18F-rhPSMA-7.3 performed within 12 weeks from C1D1 with ≥1 site with SUVmax ≥10) mCRPC with progression on prior novel hormonal agent to include at least one of the following:
• 1. PSMA SUV mean \<10
• 2. ≥1 visceral metastasis
• 3. ≥5 bone metastases
• 1. TP53
• 2. PTEN
• 3. RB1 mutation.
• 3. Age \> 18 years.
• 4. ECOG performance status of 0 to 2.
• 5. Subjects must have adequate organ and marrow function as defined below to be suitable for the randomized treatment outlined in this:
• * Absolute neutrophil count \>1000/μL; platelet count \>90 000/μL; hemoglobin \>8.5 g/dL) at screening.
• * Total bilirubin (TBIL) \<2.5 × the upper limit of normal (ULN) at screening, except subjects with documented Gilbert syndrome who must have a TBIL \<3 mg/dL
• * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 ULN at screening
• * Creatinine clearance ≥40 mL/min and/or estimated glomerular filtration rate (eGFR) ≥30
• * Albumin \>30 g/L (3.0 g/dL) at screening
• 6. Subjects receiving bisphosphonates or other approved bone-targeting therapy (e.g., denosumab) must be on a stable dose for at least 14 days before the start of study treatment.
• 7. Subjects of child-producing potential agree to use highly effective contraceptive methods (i.e., barrier contraception measures such as a male condom with spermicide during intercourse) and avoid sperm donation during the study treatment and for 3 months after the last dose of study treatment. A man is considered to be of child producing potential, unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. Partners of participants must also practice approved forms of birth control
• 8. Subjects must have the ability to understand and the willingness to sign a written informed consent form (ICF).
• 9. Members of all races and ethnic groups are eligible for this trial.
• 1. Evidence of hormone-sensitive prostate cancer (HSPC)
• 2. Evidence of small cell prostate cancer
• 3. Subjects receiving any other investigational agents.
• 4. Diagnosis of another clinically significant malignancy within the previous 2 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma and other in situ or noninvasive malignancies, as determined by the PI or Co-PI.
• 5. Subjects with brain metastases/central nervous system (CNS) disease that are treated prior to enrollment will be allowed in this clinical trial.
• 6. Known or suspected significant hypersensitivity to any components of the formulation used for Cabazitaxel, carboplatin or 177Lu-PSMA-617.
• 7. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations considered by the Investigator to limit compliance with study requirements.
• 8. Prior treatment toxicities not resolved to ≤ Grade 2 according to NCI CTCAE Version 5.0